The Government of India has recently unveiled the Next-GEN GST reforms, which will be effective from September 22, 2025. Key changes include a reduction from 12% to 5% GST on most medicines and a nil GST rate on life-saving and critical drugs. Therefore, this public notice is hereby issued by Novo Nordisk India Private Limited to all concerned using or dealing with the following pharmaceutical products. The maximum retail prices (MRP incl. of all taxes) of the products highlighted in the table below will be revised downwards by the reduction in the GST percentage from 12% to 5% with effect from September 22, 2025. The revised MRP incl. of all taxes marketed by Novo Nordisk and distributed by Abbott India Limited is published below.